Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Clin Transl Oncol. 2012 Jul;14(7):512-5. doi: 10.1007/s12094-012-0833-z.
Endometrial cancer (EC) is the most common gynaecological tumour in developing countries. Most patients with EC are diagnosed at an early stage with a low risk of relapse and overall survival at 5 years greater than 85%. Nevertheless, there is a subgroup of patients with a very poor prognosis due to the pathological features and molecular characteristics. Until now there has been no consensus regarding adjuvant treatment in EC patients, with many open questions: In which patients is it indicated? Which is the best approach: chemotherapy, radiotherapy or both? What is the right timing? Relevant clinical trials are in progress in order to answer these questions. Unfortunately, the survival of patients with metastatic or recurrent EC is quite short due to the poor responses to standard first-line chemotherapy and the lack of second lines of treatment.
子宫内膜癌（EC）是发展中国家最常见的妇科肿瘤。大多数 EC 患者在疾病早期被诊断出来，复发风险低，5 年总生存率大于 85%。然而，由于病理特征和分子特征，存在一组预后极差的患者。到目前为止，EC 患者的辅助治疗尚无共识，仍存在许多悬而未决的问题：哪些患者需要辅助治疗？最佳方法是什么：化疗、放疗还是两者结合？最佳时机是什么？目前正在进行相关的临床试验，以回答这些问题。不幸的是，转移性或复发性 EC 患者的生存时间相当短，这是由于对标准一线化疗的反应不佳以及缺乏二线治疗方案。
